Vanguard Group Inc Cellectar Biosciences, Inc. Transaction History

Vanguard Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.75 - $6.37 $6.58 Million - $11.2 Million	-1,753,800 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$4.6 - $7.8 $954,522 - $1.62 Million	-207,505 Reduced 10.58%	1,753,800 $1.21 Million
Q4 2021 Feb 14, 2022	SELL	$6.1 - $10.2 $17,720 - $29,630	-2,905 Reduced 0.15%	1,961,305 $1.3 Million
Q3 2021 Nov 12, 2021	BUY	$8.2 - $12.4 $734,933 - $1.11 Million	89,626 Added 4.78%	1,964,210 $1.82 Million
Q2 2021 Aug 13, 2021	BUY	$11.8 - $18.2 $22.1 Million - $34.1 Million	1,874,584 New	1,874,584 $2.23 Million

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $18.9M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.